Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Prognostic value of circulating mutant DNA in unresectable metastatic colorectal cancer.

Annals of surgery - 1 Feb 2010

Lefebure Benoit, Charbonnier Françoise, Di Fiore Frédéric, Tuech Jean Jacques, Le Pessot Florence, Michot Françis, Michel Pierre, Frebourg Thierry

Abstract excerpt

OBJECTIVE: No validated biologic prognostic marker is presently available in metastatic colorectal cancer (MCRC). We prospectively evaluated the prognostic value of circulating mutant DNA in 31 patients presenting an unresectable MCRC treated by chemotherapy, and we used, as tumor markers, KRAS m...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenocarcinoma
Share to Colorectal Neoplasms
Share to Methylation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Prognosis

Share to Proto-Oncogene Proteins

Share to Proto-Oncogene Proteins p21(ras)

Share to ras Proteins

Share to Tumor Suppressor Proteins

Source

Identifiers

PMID: 20010083
DOI: 10.1097/SLA.0b013e3181c35c87

Genes

KRAS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-20010083-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Prognostic value of circulating mutant DNA in unresectable metastatic colorectal cancer.PMID 20010083Read ↗

Cell-free circulating RAS mutation concentrations significantly impact the survival of metastatic colorectal cancer patients.Semantic proximity Read ↗

Circulating free DNA as biomarker and source for mutation detection in metastatic colorectal cancer.Semantic proximity Read ↗

Impact of circulating tumor DNA mutant allele fraction on prognosis in RAS‐mutant metastatic colorectal cancerSemantic proximity Read ↗

Analysis of Circulating Tumor DNA in Synchronous Metastatic Colorectal Cancer at Diagnosis Predicts Overall Patient Survival.Semantic proximity Read ↗

Clinical utility of KRAS status in circulating plasma DNA compared to archival tumour tissue from patients with metastatic colorectal cancer treated with anti-epidermal growth factor receptor therapy.Semantic proximity Read ↗

KRAS mutations in tumor tissue and plasma by different assays predict survival of patients with metastatic colorectal cancer.Semantic proximity Read ↗

Cell-free Circulating Tumor DNA Variant Allele Frequency Associates with Survival in Metastatic Cancer.Semantic proximity Read ↗

KRAS genotypic changes of circulating tumor cells during treatment of patients with metastatic colorectal cancer.Semantic proximity Read ↗

Prognostic value of circulating KRAS2 gene mutations in colorectal cancer with distant metastases.Semantic proximity Read ↗

True conversions from RAS mutant to RAS wild-type in circulating tumor DNA from metastatic colorectal cancer patients as assessed by methylation and mutational signature.Semantic proximity Read ↗

Prognostic Relevance of ctDNA RAS Mutation in Patients With Metastatic Colorectal Cancer Treated With Cetuximab.Semantic proximity Read ↗

Detection of free‐circulating tumor‐associated DNA in plasma of colorectal cancer patients and its association with prognosisSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.